Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept dose-to-target tapering in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
NL-OMON24861Not yet recruiting
- Sponsor
- Jan van Breemen Research Institute | Reade
- Start
- May 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of etanercept in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) (4 arms), sponsored by Jan van Breemen Research Institute | Reade. Primary endpoint: Proportion maintaining minimal disease activity after dose interval prolongation. Planned start May 2013; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)psoriatic arthritis (PsA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NL-OMON24861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24861.